AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib ...

where market competition is already fierce The market leader in lung cancer drugs, AstraZeneca, declined to comment without seeing more detailed clinical data about the Chinese product A victory ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

The European Commission also approved AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

The global non-small cell lung carcinoma market is poised for significant expansion over the next decade, according to new industry projections. Valued at USD 8.25 billion in 2023, the NSCLC market is ...

AstraZeneca is scheduled to report results for the first quarter on Tuesday. Here is what you need to know.